Paweł K. Kunicki

TL;DR: It is concluded that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade, and the Expert Committee concludes that Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacolimus therapy and to improve long-term outcomes for treated patients.

TL;DR: EVR trough concentrations (C0) demonstrate a good relationship with overall exposure, providing a simple and reliable index for TDM, and a fully validated liquid chromatography tandem mass spectrometry assay is the preferred method for determination of EVR C0.

TL;DR: This overview prepared by the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is intended to serve as a summary and guidance document describing the current state of the art in the TDM of ISDs.

TL;DR: In this article, the status of personalized treatment with mycophenolic acid (MPA) is discussed, including the criteria for analytics, methods to estimate exposure including pharmacometrics, potential influence of pharmacogenetics, development of biomarkers, and the practical aspects of implementation of target concentration intervention.

TL;DR: The new immunochemical PETINIA method was associated with significantly higher MPA concentrations in routine therapeutic drug monitoring samples from heart transplant patients and showed a significant difference with a reference high-performance liquid chromatography method.